Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2026-01-08 00:00:00 ET · period of report 2026-01-06 · accession 0001724310-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-08 | 2026-01-06 | DNLI | Watts Ryan J. | Pres, CEO, Dir | S - Sale | $16.50 | -35.2K | 296.8K | -11% | -$580.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-06 | S | D | 35,198 | $16.50 | 296,833 | D | — | — | (F1) Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs. (F2) Includes 184,915 Unvested RSUs. |